CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Update

CytoMed Therapeutics Limited (NASDAQ:GDTC) was the target of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 101,000 shares, a drop of 21.0% from the February 28th total of 127,800 shares. Currently, 2.1% of the shares of the company are sold short. Based on an average daily trading volume, of 194,300 shares, the days-to-cover ratio is currently 0.5 days.

CytoMed Therapeutics Stock Performance

Shares of GDTC opened at $2.24 on Monday. CytoMed Therapeutics has a 1 year low of $1.20 and a 1 year high of $4.05. The stock’s fifty day moving average price is $2.63 and its two-hundred day moving average price is $2.43.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.